Initiation of Anticoagulation in Atrial Fibrillation
Anticoagulation is indicated in patients with non‑valvular atrial fibrillation (AF) who have a CHA₂DS₂‑VASc score ≥2 in men or ≥3 in women, reflecting high thromboembolic risk [1][2][3][4]. Direct oral anticoagulants (DOACs) are preferred over warfarin as first‑line agents because of a superior benefit‑risk profile [1][5].
Risk Stratification
- CHA₂DS₂‑VASc score:
- 0 (men) or 1 (women) → no oral anticoagulant (OAC) needed.
- 1 (men) or 2 (women) → consider OAC after individual bleeding risk assessment.
-
≥2 (men) or ≥3 (women) → OAC recommended.
-
Bleeding risk: Evaluate using tools such as HAS‑BLED; high bleeding risk prompts mitigation strategies rather than withholding OAC outright [6].
Anticoagulant Choice
- DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) are first‑line for most patients without contraindications [1][5].
- Warfarin reserved for patients with mechanical heart valves, severe mitral stenosis, or contraindications to DOACs.
Initiation Timing
- Start OAC promptly after AF diagnosis in eligible patients; no required waiting period.
- In the setting of recent ischemic stroke, initiate OAC after 3–14 days depending on infarct size and imaging, balancing recurrent stroke versus hemorrhagic transformation risk (guideline‑based approach) [2][6].
Special Populations
- Elderly: Use reduced DOAC dosing per renal function and age criteria; benefits of stroke prevention generally outweigh bleeding risk when dosing is appropriate [6].
- Renal impairment: Adjust DOAC dose or select warfarin if creatinine clearance <15 mL/min.
Monitoring and Follow‑up
- Reassess CHA₂DS₂‑VASc and bleeding risk annually or after clinical change.
- Verify adherence, renal function, and potential drug interactions at each visit.
Key point: Initiate a DOAC promptly in all patients with CHA₂DS₂‑VASc ≥2 (men) or ≥3 (women) unless contraindicated, and tailor dosing to age, renal function, and bleeding risk.